Less is More. Just a thought.
Monday, October 9, 2017
Sunday, October 8, 2017
Pharma...
Cancer drugs cost far less to develop than industry-backed research asserts, an analysis published asserts. Research and development costs are a major reason that drug companies justify high prices, so this dispute has a direct bearing on the cost of medical care.
The analysis, published in the current issue of JAMA Internal Medicine, concludes that it costs, on average, $650 million to develop a new cancer drug. The authors add in another $100 million or so to account for income those companies could have had if that money had been invested in the stock market instead of in new products.
That total is far lower than the $2.7 billion figure that the drug industry frequently points to when it justifies the soaring cost of medicine.
Prices of medications is higher since the market is not open and free. This is why in Canada and other similar countries prices are one third of the American market.
So the revenue from Marketing in US is more rewarding than R&D which is not the case in Europe. Just a thought.
Glass...
Nothing much to talk about now a days. So here comes the next Hurricane. Days of continue pounding on what possibly will happen in the coming three days.
Nothing else can save us except a new election.
Saturday, October 7, 2017
Marketing..
Shares of $17 billion drug stock Mylan NV (MYL) are in rally-mode , breaking out to nearly 19% gains on the heels of an FDA approval.
Mylan scored the FDA's blessing on its generic copy of Teva Pharmaceutical's (TEVA ) blockbuster multiple-sclerosis drug Copaxone, sparking a selloff in Teva as investors worry that generic competition will severely damage the $3.6 billion revenue stream Teva has banked on Copaxone in the last 12 months.
More importantly for Mylan shareholders, the FDA approval rights what's been a very shaky ship in 2017. Before today, Mylan had been staring down a 15% reduction in market value year to date, trailing the rest of the healthcare sector by a massive 35%. Wednesday's double-digit rally in Mylan helps to bridge that gap.
And there are signs of more upside ahead for Mylan from here. Now the marketing begins.
Traffickers...
Over the summer, Italy began funneling cash and logistical support to two major militias in Sabratha after they agreed to stop their involvement in human trafficking and instead act as a police force against it, stopping migrant boats.
It began when a Libyan militia intercepted a group of human traffickers offshore. That confrontation has spiraled into a weeks-long battle among rival militias for control of a Libyan coastal city that has left dozens dead.
This is a war that started between human traffickers, then snowballed into an ideological and political one. But voices in Libya decried the deal, fearing that the salaries and supplies would enrich the militias and make them more powerful. The boost to one side threw off the balance of power in Sabratha.
We willingly destroyed the Country of Libya and the outcome is misery all over.
Friday, October 6, 2017
Subscribe to:
Posts (Atom)